Antilipoxygenase activity of copper complexes of aminoalkanoate type.
OBJECTIVE
Lipoxygenases (EC 1.13.11.12, LOX) catalyze the hydroperoxidation of polyunsaturated fatty acids (PUFA). This reaction leads to the production of conjugated hydro peroxide dienes of PUFA. In animals, LOX generate leukotriens (LT) and lipoxins, which belong to inflammatory mediators. It is believed that restricting LT synthesis by inhibition of LOX would have therapeutic utility for the treatment of a variety of inflammatory conditions (e.g. asthma, rheumatoid arthritis, psoriasis).


RESULTS
The process of production and elimination of radical intermediates in vitro can be monitored by determination of LOX activity. We assessed the concentration of PUFA hydroperoxides in our system with LOX-catalyzed enzyme reaction spectrophotometrically. The inhibition of LOX activity (LOX from cytosol fraction of rat lungs) with selected N-salicylideneaminoalkanoatocopper(II) complexes was tested. In our experiments, all compounds tested showed an inhibitory effect on LOX catalyzed hydroperoxidation of PUFA. Cu(II) (from CuSO(4).5H(2)O dilution) ions also inhibited this enzyme reaction, but all compounds studied had a 10 times higher anti-LOX activity. The most effective of these complexes was monohydrate aqua-(N-salicylidene-L-a-alaninato)copper(II) complex [Cu(sal-L-alpha-ala)(H(2)O)].H(2)O with IC(50) 1.86 x 10(-4) mol/l.


CONCLUSIONS
These complexes are known for their anti-phlogistic and radioprotective properties and they can be classified as potential anti-radical compounds. The structure of these complexes is similar to the active site of Cu,Zn-SOD (superoxide dismutase) and superoxide radical scavenger activity of these complexes is known. We found that these copper complexes were capable to inhibit LOX activity, which may be related with their anti-radical properties.
Ponist
Silvester
S
Institute of Experimental Pharmacology, Slovak Academy of Sciences, Bratislava, Slovakia. exfasipo@savba.sk
Valentová
Jindra
J
Bezáková
Lýdia
L
Oblozinský
Marek
M
D000818:Animals; D003300:Copper / Q000494:pharmacology*; D005231:Fatty Acids, Unsaturated / Q000378:metabolism; D008084:Lipoxygenase / Q000378:metabolism; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology*; D008954:Models, Biological; D009942:Organometallic Compounds / Q000494:pharmacology*; D051381:Rats
D005231:Fatty Acids, Unsaturated; D016859:Lipoxygenase Inhibitors; D009942:Organometallic Compounds; C520068:monohydrate aqua-(N-salicylidene-taurine)copper(II) complex; D003300:Copper; D008084:Lipoxygenase